BMS Q1 2025 Results: Opdivo Sales Up 12% Despite Overall Revenue Decline
US-based multinational Bristol-Myers Squibb (BMS, NYSE: BMY) released its Q1 2025 financial results, showing a...
NYSE: BMY
BMS’s Cobenfy Shows Promise in Phase III ARISE Trial for Schizophrenia
Bristol-Myers Squibb (BMS, NYSE: BMY) has announced top-line results from the Phase III ARISE trial...
BMS Secures NMPA Approval for Opdivo in Resectable NSCLC Neoadjuvant Therapy
Bristol-Myers Squibb (BMS, NYSE: BMY) has announced additional indication approval from China’s National Medical Products...
BMS Faces Phase III Setback for Camzyos in Non-Obstructive HCM Study
US pharmaceutical giant Bristol-Myers Squibb (BMS; NYSE: BMY) has reported a setback in the Phase...
Bristol-Myers Squibb Wins FDA Approval for Opdivo-Yervoy Combo in First-Line HCC Treatment
Bristol-Myers Squibb (BMS, NYSE: BMY) has secured another indication approval from the US Food and...
Bristol-Myers Squibb’s Opdivo/Yervoy Combo Approved for MSI-H Colorectal Cancer
Bristol-Myers Squibb (BMS, NYSE: BMY) announced this week that the US Food and Drug Administration...
BMS’s Opdivo/Yervoy Combo Approved by NMPA for First-Line HCC Treatment
Bristol-Myers Squibb (BMS, NYSE: BMY) announced that it has received approval from China’s National Medical...
BMS’s Breyanzi Approved by EC for Relapsed or Refractory Follicular Lymphoma
US giant Bristol-Myers Squibb (BMS; NYSE: BMY) announced receiving another indication approval from the European...
Bristol-Myers Squibb’s Opdivo/Yervoy Combo Approved by EU for Hepatocellular Carcinoma
US giant Bristol-Myers Squibb (BMS, NYSE: BMY) announced receiving marketing approval from the European Commission...
Bristol-Myers Squibb’s Opdivo-Yervoy Combo Nears FDA Approval for MSI-H Colorectal Cancer
Bristol-Myers Squibb (BMS, NYSE: BMY) announced that the U.S. FDA has accepted its filing for...
Bristol-Myers Squibb’s Opdivo Shows Survival Benefit in CheckMate-816 Study
Bristol-Myers Squibb (BMS, NYSE: BMY) announced the final analysis of overall survival (OS) data from...
Bristol-Myers Squibb Releases Five-Year Data on Sotyktu’s Long-Term Efficacy and Safety
In a recent announcement, US pharmaceutical giant Bristol-Myers Squibb (BMS, NYSE: BMY) unveiled the latest...
Bristol Myers Squibb’s Opdualag Fails to Meet Primary Endpoint in Melanoma Study
US pharmaceutical major Bristol-Myers Squibb (BMS, NYSE: BMY) provided an update on the RELATIVITY-098 study...
Bristol-Myers Squibb’s Breyanzi Hits Primary Endpoint in Lymphoma Study
Bristol-Myers Squibb (BMS, NYSE: BMY) reported positive results from the Phase II TRANSCEND FL study...
Bristol-Myers Squibb Posts 8% Q4 Revenue Growth, Driven by Opdivo and New Products
Bristol-Myers Squibb (BMS, NYSE: BMY) reported an 8% year-on-year (YOY) increase in revenues to USD...
Sichuan Biokin Re-submits IPO Application to Hong Kong Stock Exchange
Sichuan Biokin Pharmaceutical Co., Ltd (SHA: 688506) has announced that it has resubmitted its application...
Bristol-Myers Squibb Exercises License for ArsenalBio’s AB-4000 Series
US-based cell therapy company Arsenal Biosciences, Inc. has announced that Bristol-Myers Squibb (BMS, NYSE: BMY)...
Bristol-Myers Squibb’s Opdivo Qvantig Receives FDA Approval for Expanded Indications
Global biopharmaceutical company Bristol-Myers Squibb (BMS, NYSE: BMY) has announced that the US Food and...
Bristol-Myers Squibb’s Sotyktu Meets Primary Endpoints in POETYK PsA Studies
US pharmaceutical major Bristol-Myers Squibb (BMS; NYSE: BMY) has announced positive results from the pivotal...
Bristol-Myers Squibb’s Opdivo-Yervoy Combo Approved by EC for MSI-H/mCRC
Global biopharmaceutical company Bristol-Myers Squibb (BMS, NYSE: BMY) has announced that it has received marketing...